Global Vaccine Delivery Devices Market Outlook to 2027
Vaccine delivery devices are the set of devices that are employed to inject or supply vaccines into a body with minimal risk of contamination. According to MarketStack Reports the global market for vaccine delivery devices market is being driven by the developments in the global immunization programs and successful trials of the COVID-19 Vaccine.
The vaccination program for COVID-19 along with other deadly diseases are likely to drive the market in the short-medium term. In recent years, there has been a remarkable growth in the availability of the vaccine across all corners of the globe. The uptake of both new and underused vaccines is increasing. The current immunization program prevents 2-3 million deaths every year globally. The initiatives taken to tackle the supply chain issues have contributed to a great extent. For instance, the formation of local groups and sending them to each district with targets has helped in reaching out to a maximum of infants and women. For most of the essential vaccines, the global coverage is over 80%. Though the rates of vaccination are yet to be improved. One of the major developments in the global immunization program is “Immunization Agenda 2030 (IA2030)”. It has an objective of setting up a strategy for vaccines and immunization for the decade 2021-2030 and is expected to come into effect after WHA endorsement.
The main strategy of IA2030 is to align the activities of stakeholders at all levels including communities, national, regional, and global. In the year 2019, around 85% of the infants received 3 doses of the diphtheria-tetanus-pertussis (DTP3) vaccine. 125 member states of the World Health Organization reached 90% coverage of the DTP3 vaccine. In 2019, among all the major diseases, Rotavirus’s global vaccination coverage was relatively low at 39%. However, in 2019, 14 million infants have not received an initial dose of DTP vaccine due to lack of access to health services, and over 5.7 million infants were partially vaccinated. Around 60% of such cases were found in 10 countries including Angola, Brazil, the Republic of Congo, Ethiopia, India, Indonesia, Nigeria, Mexico, Pakistan, and the Philippines. Different bodies of the United Nations, NGOs, private organizations, and governments are working together to increase immunization among the population to beat the major diseases. The coverage of vaccine is over 90% in all developed countries and is relatively low in developing countries. In some low-income economies, the coverage is below 50%. The ongoing changes in the strategies to expand the vaccine coverage and the upcoming vaccine for COVID-19 is likely to continue driving the market for the global vaccine delivery devices market in the coming years. However, the high costs of micro-needles are likely to hinder the growth of the market.
In terms of geography, Asia-Pacific is likely to witness the highest growth during the forecast period. The United States has a profound presence of vaccine delivery device manufacturers and suppliers in the country. The overall industry is known for the quality and the standards set by the authorities and governing bodies. In response to the outbreak of the COVID-19 pandemic and the development of its vaccine, in July 2020, BD partnered with the US government to develop manufacturing lines for vaccine-delivery systems. As a part of this initiative, BARDA (Biomedical Advanced Research and Development Authority) will invest USD 42 million into a USD 70 million capital project to expand the operations and manufacturing capacity of BD in Nebraska. In March 2020, the government of the United States agreed to invest over half a billion in tax dollars in ApiJect Systems America. During the approval for investment, its injector was not approved by federal health authorities and the company had not yet set up a factory to manufacture the vaccine delivery devices.
The United States’ government has included vaccination as a core component of foreign policy, and as a foreign aid priority for a long time. The Trump administration raised requests to cut global health funding, including for the U.S. agencies involved in global vaccination campaigns. However, with the new administration coming to power, the funds are likely to come back to the previous levels. As a government, the U.S. government is the second-leading government donor to global vaccination campaigns. Through annual appropriations to the Department of Health and Human Services (HHS) and the Department of State, Congress funds global immunization activities through the Centers for Disease Control and Prevention (CDC), the United States Agency for International Development (USAID), and GAVI. With the approval of the Vaccine by Pfizer in the United States, there is a need to vaccinate 300 million Americans in the country. This is likely to add up to the demand for vaccine delivery devices. Depending on the number of doses required, the number of vaccine delivery devices may vary.
The global market for vaccine delivery devices is led by major players including Valeritas, Becton, Dickinson and Company, Kindeva Drug Delivery, Pharmajet, Inc. Gerresheimer AG, Schott Vaxxas, and Corium International, Inc. among others.
The vaccination program for COVID-19 along with other deadly diseases are likely to drive the market in the short-medium term. In recent years, there has been a remarkable growth in the availability of the vaccine across all corners of the globe. The uptake of both new and underused vaccines is increasing. The current immunization program prevents 2-3 million deaths every year globally. The initiatives taken to tackle the supply chain issues have contributed to a great extent. For instance, the formation of local groups and sending them to each district with targets has helped in reaching out to a maximum of infants and women. For most of the essential vaccines, the global coverage is over 80%. Though the rates of vaccination are yet to be improved. One of the major developments in the global immunization program is “Immunization Agenda 2030 (IA2030)”. It has an objective of setting up a strategy for vaccines and immunization for the decade 2021-2030 and is expected to come into effect after WHA endorsement.
The main strategy of IA2030 is to align the activities of stakeholders at all levels including communities, national, regional, and global. In the year 2019, around 85% of the infants received 3 doses of the diphtheria-tetanus-pertussis (DTP3) vaccine. 125 member states of the World Health Organization reached 90% coverage of the DTP3 vaccine. In 2019, among all the major diseases, Rotavirus’s global vaccination coverage was relatively low at 39%. However, in 2019, 14 million infants have not received an initial dose of DTP vaccine due to lack of access to health services, and over 5.7 million infants were partially vaccinated. Around 60% of such cases were found in 10 countries including Angola, Brazil, the Republic of Congo, Ethiopia, India, Indonesia, Nigeria, Mexico, Pakistan, and the Philippines. Different bodies of the United Nations, NGOs, private organizations, and governments are working together to increase immunization among the population to beat the major diseases. The coverage of vaccine is over 90% in all developed countries and is relatively low in developing countries. In some low-income economies, the coverage is below 50%. The ongoing changes in the strategies to expand the vaccine coverage and the upcoming vaccine for COVID-19 is likely to continue driving the market for the global vaccine delivery devices market in the coming years. However, the high costs of micro-needles are likely to hinder the growth of the market.
In terms of geography, Asia-Pacific is likely to witness the highest growth during the forecast period. The United States has a profound presence of vaccine delivery device manufacturers and suppliers in the country. The overall industry is known for the quality and the standards set by the authorities and governing bodies. In response to the outbreak of the COVID-19 pandemic and the development of its vaccine, in July 2020, BD partnered with the US government to develop manufacturing lines for vaccine-delivery systems. As a part of this initiative, BARDA (Biomedical Advanced Research and Development Authority) will invest USD 42 million into a USD 70 million capital project to expand the operations and manufacturing capacity of BD in Nebraska. In March 2020, the government of the United States agreed to invest over half a billion in tax dollars in ApiJect Systems America. During the approval for investment, its injector was not approved by federal health authorities and the company had not yet set up a factory to manufacture the vaccine delivery devices.
The United States’ government has included vaccination as a core component of foreign policy, and as a foreign aid priority for a long time. The Trump administration raised requests to cut global health funding, including for the U.S. agencies involved in global vaccination campaigns. However, with the new administration coming to power, the funds are likely to come back to the previous levels. As a government, the U.S. government is the second-leading government donor to global vaccination campaigns. Through annual appropriations to the Department of Health and Human Services (HHS) and the Department of State, Congress funds global immunization activities through the Centers for Disease Control and Prevention (CDC), the United States Agency for International Development (USAID), and GAVI. With the approval of the Vaccine by Pfizer in the United States, there is a need to vaccinate 300 million Americans in the country. This is likely to add up to the demand for vaccine delivery devices. Depending on the number of doses required, the number of vaccine delivery devices may vary.
The global market for vaccine delivery devices is led by major players including Valeritas, Becton, Dickinson and Company, Kindeva Drug Delivery, Pharmajet, Inc. Gerresheimer AG, Schott Vaxxas, and Corium International, Inc. among others.
1. Executive Summary
2. Research Scope and Methodology
2.1 Aim & Objective of the study
2.2 Market Definition
2.3 Study Information
2.4 General Study Assumptions
2.5 Research Phases
3. Market Analysis
3.1 Introduction
3.2 Market Dynamics
3.2.1 Drivers
3.2.2 Restraints
3.3 Market Trends & Developments
3.4 Market Opportunities
3.5 Feedstock Analysis
3.6 Regulatory Policies
3.7 Analysis of Covid-19 Impact
4. Industry Analysis
4.1 Supply Chain Analysis
4.2 Porter's Five Forces Analysis
4.2.1 Competition in the Industry
4.2.2 Potential of New Entrants into the Industry
4.2.3 Bargaining Power of Suppliers
4.2.4 Bargaining Power of Consumers
4.2.5 Threat of substitute products
5. Market Segmentation & Forecast
5.1 By Type
5.1.1 Jet Injectors
5.1.2 Microneedles
5.1.3 Syringes
5.1.4 Others
5.2 By Route of Administration
5.2.1 Intradermal Vaccination
5.2.2 Intramuscular Vaccination
5.2.3 Oral Vaccination
5.2.4 Subcutaneous Vaccination
5.2.5 Others
5.3 By End-user
5.3.1 Clinics
5.3.2 Hospitals
5.3.3 Others
6. Regional Market Analysis
6.1 North America
6.1.1 United States
6.1.2 Canada
6.1.3 Mexico
6.2 Europe
6.2.1 Germany
6.2.2 United Kingdom
6.2.3 Italy
6.2.4 France
6.2.5 Russian Federation
6.2.6 Nordic Countries
6.2.7 Rest of Europe
6.3 Asia-Pacific
6.3.1 China
6.3.2 India
6.3.3 Japan
6.3.4 South Korea
6.3.5 Rest of Asia-Pacific
6.4 South America
6.4.1 Brazil
6.4.2 Argentina
6.4.3 Rest of South America
6.5 Middle East & Africa
6.5.1 South Africa
6.5.2 Saudi Arabia
6.5.3 Rest of Middle East & Africa
7. Key Company Profiles
7.1 KINDEVA DRUG DELIVERY
7.2 Antares Pharma
7.3 Becton, Dickinson and Company
7.4 Consort Medical PLC
7.5 Corium, Inc.
7.6 Gerresheimer AG
7.7 Ichor Medical Systems, Inc.
7.8 INOVIO Pharmaceuticals
7.9 ICONOVO AB
7.10 Panacea Pharmaceuticals, Inc.
7.11 PharmaJet, Inc.
7.12 Schott AG
7.13 Valeritas
7.14 Vaxxas
7.15 West Pharmaceutical Services, Inc.*List of companies is not exhaustive
8. Competitive Landscape
8.1 List of Notable Players in the Market
8.2 M&A, JV, and Agreements
8.3 Market Share Analysis
8.4 Strategies of Key Players
9. Conclusions and Recommendations
2. Research Scope and Methodology
2.1 Aim & Objective of the study
2.2 Market Definition
2.3 Study Information
2.4 General Study Assumptions
2.5 Research Phases
3. Market Analysis
3.1 Introduction
3.2 Market Dynamics
3.2.1 Drivers
3.2.2 Restraints
3.3 Market Trends & Developments
3.4 Market Opportunities
3.5 Feedstock Analysis
3.6 Regulatory Policies
3.7 Analysis of Covid-19 Impact
4. Industry Analysis
4.1 Supply Chain Analysis
4.2 Porter's Five Forces Analysis
4.2.1 Competition in the Industry
4.2.2 Potential of New Entrants into the Industry
4.2.3 Bargaining Power of Suppliers
4.2.4 Bargaining Power of Consumers
4.2.5 Threat of substitute products
5. Market Segmentation & Forecast
5.1 By Type
5.1.1 Jet Injectors
5.1.2 Microneedles
5.1.3 Syringes
5.1.4 Others
5.2 By Route of Administration
5.2.1 Intradermal Vaccination
5.2.2 Intramuscular Vaccination
5.2.3 Oral Vaccination
5.2.4 Subcutaneous Vaccination
5.2.5 Others
5.3 By End-user
5.3.1 Clinics
5.3.2 Hospitals
5.3.3 Others
6. Regional Market Analysis
6.1 North America
6.1.1 United States
6.1.2 Canada
6.1.3 Mexico
6.2 Europe
6.2.1 Germany
6.2.2 United Kingdom
6.2.3 Italy
6.2.4 France
6.2.5 Russian Federation
6.2.6 Nordic Countries
6.2.7 Rest of Europe
6.3 Asia-Pacific
6.3.1 China
6.3.2 India
6.3.3 Japan
6.3.4 South Korea
6.3.5 Rest of Asia-Pacific
6.4 South America
6.4.1 Brazil
6.4.2 Argentina
6.4.3 Rest of South America
6.5 Middle East & Africa
6.5.1 South Africa
6.5.2 Saudi Arabia
6.5.3 Rest of Middle East & Africa
7. Key Company Profiles
7.1 KINDEVA DRUG DELIVERY
7.2 Antares Pharma
7.3 Becton, Dickinson and Company
7.4 Consort Medical PLC
7.5 Corium, Inc.
7.6 Gerresheimer AG
7.7 Ichor Medical Systems, Inc.
7.8 INOVIO Pharmaceuticals
7.9 ICONOVO AB
7.10 Panacea Pharmaceuticals, Inc.
7.11 PharmaJet, Inc.
7.12 Schott AG
7.13 Valeritas
7.14 Vaxxas
7.15 West Pharmaceutical Services, Inc.*List of companies is not exhaustive
8. Competitive Landscape
8.1 List of Notable Players in the Market
8.2 M&A, JV, and Agreements
8.3 Market Share Analysis
8.4 Strategies of Key Players
9. Conclusions and Recommendations
